Australia · Delayed Price · Currency is AUD ImpediMed Statistics
Total Valuation
ImpediMed has a market cap or net worth of AUD 95.70 million. The enterprise value is 88.01 million.
| Market Cap | 95.70M |
| Enterprise Value | 88.01M |
Important Dates
The next estimated earnings date is Sunday, October 19, 2025.
| Earnings Date | Oct 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ImpediMed has 2.04 billion shares outstanding. The number of shares has decreased by -0.13% in one year.
| Current Share Class | 2.04B |
| Shares Outstanding | 2.04B |
| Shares Change (YoY) | -0.13% |
| Shares Change (QoQ) | -99.90% |
| Owned by Insiders (%) | 5.99% |
| Owned by Institutions (%) | 14.30% |
| Float | 1.81B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.52 |
| PB Ratio | 4.67 |
| P/TBV Ratio | 12.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.79 |
| EV / Sales | 6.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.98 |
Financial Position
The company has a current ratio of 4.86, with a Debt / Equity ratio of 0.71.
| Current Ratio | 4.86 |
| Quick Ratio | 4.56 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.99 |
| Interest Coverage | -19.77 |
Financial Efficiency
Return on equity (ROE) is -75.89% and return on invested capital (ROIC) is -37.41%.
| Return on Equity (ROE) | -75.89% |
| Return on Assets (ROA) | -32.44% |
| Return on Invested Capital (ROIC) | -37.41% |
| Return on Capital Employed (ROCE) | -63.91% |
| Revenue Per Employee | 165,247 |
| Profits Per Employee | -301,779 |
| Employee Count | 77 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 2.16 |
Taxes
In the past 12 months, ImpediMed has paid 26,000 in taxes.
| Income Tax | 26,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.34% in the last 52 weeks. The beta is 2.27, so ImpediMed's price volatility has been higher than the market average.
| Beta (5Y) | 2.27 |
| 52-Week Price Change | -20.34% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.04 |
| Relative Strength Index (RSI) | 68.99 |
| Average Volume (20 Days) | 2,030,878 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ImpediMed had revenue of AUD 12.72 million and -23.24 million in losses. Loss per share was -0.01.
| Revenue | 12.72M |
| Gross Profit | 10.98M |
| Operating Income | -23.01M |
| Pretax Income | -23.21M |
| Net Income | -23.24M |
| EBITDA | -22.78M |
| EBIT | -23.01M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 22.18 million in cash and 14.49 million in debt, giving a net cash position of 7.69 million or 0.00 per share.
| Cash & Cash Equivalents | 22.18M |
| Total Debt | 14.49M |
| Net Cash | 7.69M |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 20.50M |
| Book Value Per Share | 0.01 |
| Working Capital | 21.85M |
Cash Flow
In the last 12 months, operating cash flow was -14.65 million and capital expenditures -60,000, giving a free cash flow of -14.71 million.
| Operating Cash Flow | -14.65M |
| Capital Expenditures | -60,000 |
| Free Cash Flow | -14.71M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 86.25%, with operating and profit margins of -180.82% and -182.62%.
| Gross Margin | 86.25% |
| Operating Margin | -180.82% |
| Pretax Margin | -182.42% |
| Profit Margin | -182.62% |
| EBITDA Margin | -178.99% |
| EBIT Margin | -180.82% |
| FCF Margin | n/a |
Dividends & Yields
ImpediMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.13% |
| Shareholder Yield | n/a |
| Earnings Yield | -24.28% |
| FCF Yield | -15.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImpediMed has an Altman Z-Score of -9.97 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.97 |
| Piotroski F-Score | 2 |